ITGRInteger Holdings Corporation
$126.61+23% 1Y
$126.61
$63.3252 weeks$126.65
The financials
Integer Holdings Corporation by the numbers
Integer Holdings Corporation (ITGR) reported revenue of $464M in Q2 2026 (quarter ended Jul 3, 2026), down 2.6% from the same quarter a year earlier. That came with a gross margin of 24% and net income of $24M (5.1% of revenue). For the full year FY2025, revenue was $1.85B (+8.0% year on year) and net income $103M. Its largest product in Q2 2026 was Cardio And Vascular at $280M, 60% of the disclosed total, well ahead of Cardiac Rhythm Management Neuromodulation at 37%. The next results filing is expected around Oct 22, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $464M | $476M | −2.6% |
| Gross profit | $113M | $129M | −13% |
| Operating income | $35M | $59M | −42% |
| Net income | $24M | $37M | −36% |
| Diluted EPS | $0.69 | $1.04 | −34% |
| Product | Revenue | Share |
|---|---|---|
| Cardio And Vascular | $280M | 60% |
| Cardiac Rhythm Management Neuromodulation | $174M | 37% |
| Other Markets | $10M | 2.2% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $464.1M (+5.6%)
Cardiac Rhythm Management Neuromodulation grew +1.00% year on yearOther Markets -43% year on year
Segment Latestquarter on quarteryear on year
- Cardio And Vascular$280.3M$280.3Mquarter on quarter +7.1%year on year -2.3%+7.1%-2.3%
- Cardiac Rhythm Management Neuromodulation$173.7M$173.7Mquarter on quarter +3.2%year on year +1.00%+3.2%+1.00%
- Other Markets$10.1M$10.1Mquarter on quarter +5.3%year on year -43%+5.3%-43%
On our screens:Quality at a reasonable price